PT - JOURNAL ARTICLE AU - Szydlo-Shein, Andrea AU - de Estrada, Blanca Sanz-Magallón Duque AU - Rosenheim, Joshua AU - Turner, Carolin T. AU - Tsaliki, Evdokia AU - Lipman, Marc C. I. AU - Kunst, Heinke AU - Pollara, Gabriele AU - Elks, Philip M. AU - Levraud, Jean-Pierre AU - Payne, Elspeth M. AU - Noursadeghi, Mahdad AU - Tomlinson, Gillian S. TI - Type I interferon responses contribute to immune protection against mycobacterial infection AID - 10.1101/2024.06.26.24309490 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.26.24309490 4099 - http://medrxiv.org/content/early/2024/06/26/2024.06.26.24309490.short 4100 - http://medrxiv.org/content/early/2024/06/26/2024.06.26.24309490.full AB - Reasons for the spectrum of severity of active tuberculosis (TB) disease are incompletely understood. We sought to identify master regulators of host immune responses that determine disease severity in pulmonary TB. We performed molecular profiling of human in vivo immune responses to discover associations with the extent of radiographic TB disease in a patient cohort. We then undertook mechanistic studies to test causality for the observed associations using the zebrafish larval Mycobacterium marinum infection model. Transcriptional profiling of human immune recall responses to tuberculin skin test (TST) challenge, a surrogate for immune responses to TB in the lung, revealed that type I interferon activity in the TST transcriptome was inversely associated with radiological disease severity. Abrogation of type I interferon signalling, achieved by CRISPR-mediated mutagenesis of stat2, led to increased susceptibility of zebrafish larvae to M. marinum infection, as a result of reduced recruitment of myeloid cells required to restrict mycobacterial growth, to the site of disease. Our data support a host protective role for type I interferon responses in mycobacterial infection, with potential applications for risk-stratification of adverse outcomes and development of a host-directed therapy to mitigate against severe disease.One Sentence Summary Type I interferon responses contribute to host immune protection in mycobacterial infection by recruitment of myeloid cells to the site of disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGST is supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). MN is supported by the Wellcome Trust (207511/Z/17/Z). PME is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (105570/Z/14/Z). J-PL is supported by Fondation pour la Recherche Medicale (grant EQU202203014646). MN and GST are also supported by NIHR Biomedical Research Centre Funding to University College Hospitals NHS Foundation Trust and University College London. This research was funded in whole, or in part, by the Wellcome Trust [207511/Z/17/Z, 105570/Z/14/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The London Bloomsbury Research Ethics Committee gave ethical approval for this work (16/LO/0776).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesHuman RNAseq data are already available in the ArrayExpress repository under accession number E-MTAB-6816. Zebrafish RNAseq data will be made available in ArrayExpress at the time of peer reviewed publication of the manuscript. The source code and manual for QuantiFish software used for analysis of bacterial burden and dissemination in zebrafish larvae are available at https://github.com/DavidStirling/QuantiFish. The ImageJ macro used to generate montages from the Hermes images and source code and manual for the Python script used for analysis of steady state cell numbers and cellular recruitment in zebrafish are available at https://github.com/AndSzyShe/particle_analysis. Source data for figure panels with fewer than 20 data points are available in Data file S1.https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-6816